To the editor: Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular disease (CVD) often co-occur, presenting complex management challenges due to concerns over the effects of beta-blockers on respiratory function. Recent studies have evaluated the safety and efficacy of beta-blockers, particularly cardioselective ones, in this patient population. These medications offer advantages in managing cardiovascular conditions without exacerbating COPD symptoms and may lead to improved survival outcomes.
